Administrator

Administrator

The Childhood Brain Tumor Foundation

20312 Watkins Meadow Drive
Germantown, MD 20876
(301) 515-2900
Toll-free: (877) 217-4166
This email address is being protected from spambots. You need JavaScript enabled to view it.">E-mail the Foundation

For problems using the site please contact our This email address is being protected from spambots. You need JavaScript enabled to view it..

Many children suffer debilitating side effects from their brain tumors and treatments.  Cures are desperately needed. Help us support important research that will lead to cures for children with brain tumors. Donating is made easy through our Give Online button or by mailing us our downloadable donation form. All donations made in honor of or in memory of someone will be acknowledged to the family or loved one. E-mail us at This email address is being protected from spambots. You need JavaScript enabled to view it. or call 877-217-4166 with your special interests regarding research and information.

Contact us if you need additional information about pediatric brain tumors; specific and in general.

Mailing Address: CBTF, 20312 Watkins Meadow Dr, Germantown, MD 20876


GIVE ONLINE is our secure online donation button for CBTF supporters. A special message or instructions may be included in the message box.

Donating via stock option is also available through GIVE ONLINE, or contact us for our broker. Donations may also be made in your will.

GiveOnline3 shadowmatch largerWe accept stock donations, contact us for our account information and broker's contact information via TD Ameritrade.

The Childhood Brain Tumor Foundation depends upon public donations to continue its work. Our online donation form provides several donation options to support research and education. Making a donation through our secure server is fast and easy, and when we receive your donation, we will send you an acknowledgment in the mail for tax purposes.

Click on the Give Online button above to support pediatric brain tumor research/education as a general or event donation, in honor of, or in memory of someone.


Amazon Smile

When you shop at AmazonSmile, Amazon donates 0.5% of the purchase price to Childhood Brain Tumor Foundation. Bookmark the link http://smile.amazon.com/ch/52-2122976 and support us every time you shop.


If you prefer to mail in your donation, you can download and print the donation form (Word) (pdf) and mail it in.

 Provide support to children suffering from brain tumors. Help fund vital scientific
and clinical research. Through research, there is hope for a cure.


CBTF funds top-quality research and accepts applications for all pediatric tumors. We receive applications through our competitive process and each proposal is peer-reviewed by brain tumor experts. Contact us at This email address is being protected from spambots. You need JavaScript enabled to view it. or call 877-217-4166 if you need general or specific information, have any special interests or questions.

        Services Provided by the Childhood Brain Tumor Foundation

  • Annual support for scientific and clinical research
  • Tri-annual newsletter with reporting of funded research, events, educational articles, and personal stories
  • Family Retreat Day and/or conferences
  • Childhood Cancer Ombudsman Program, (CCOP) to help with health insurance analysis and application, employment, and educational difficulties that may arise during or after treatment
  • Related Articles and Stories
  • Fund-raisers, Events
  • Provides additional specific information about brain tumors or treatments upon request
  • Sponsorship for the International Symposium on Pediatric Neuro-Oncology, 1996, 2000, 2002, 2004, 2006, 2008, 2010, 2012, and [2014]
  • Sponsorship for the Society for Neuro-Oncology annually since 2000 for the International Program.

 

The Childhood Brain Tumor Foundation and Children’s National Medical Center partnered again in the collaboration of the Childhood Cancer Survivorship Conference, Focus on Brain Tumors, on Sunday, May 22, 2011.  The comprehensive conference included excellent topics and expert speakers from the region who shared their knowledge.  

If you are interested in any information that was covered, please contact the foundation to inquire about any of the available copies of Power Point presentations,  This email address is being protected from spambots. You need JavaScript enabled to view it..

We look forward to future collaborations that provide vital information to families.

On November 10, 2012, the Childhood Brain Tumor Foundation held its annual fall Casino Gala since inception.  The event included plenty of activity, live band, silent auction, buffet dinner, open-bar, and our casino games.  The CBTF Board of Directors and Advisory were pleased to recognize three oustanding volunteers this year. 

We are deeply appreciative for the sponsorship support given by Whittles Physical Therapy, Second Chance Band/UVFD/JKS Spirit Fund, Children's National Foundation, and other anonymous sponsors.  It is through the support of businesses, friends, families, medical professionals, and general supporters that we will continue forward with our vital program initiatives.  Together, with all of our supporters, we will make a difference and we will help fund important research initiatives to find a cure.

Thank you to all of our event supporters! Thanks to all who support our organization every day!

Please click on the following links to read about CBTF funded grants (Unless otherwise noted, most studies are funded for up to two years):

Additional summaries are available in our fall newsletter editions.

Clinical and biological relevance of PI3K/AKT/mTOR

pathway activation in pilocytic astrocytoma

Fausto J. Rodriguez M.D., Johns Hopkins School of Medicine

(Report from funding, 2011-2012)

This study has been published in two journals.

 

Pilocytic astrocytomas (PA) are low grade neoplasms that represent the most frequent gliomas in children and your adults. Most of these tumors have an excellent outcome after gross total resection. However a subset progress clinically despite standard treatments, particularly those that arise in anatomic locations where a complete resection is not possible. Therefore, a basic understanding of the molecular mechanisms responsible for PA biology is needed in order to provide novel curative treatments.

 

The most frequent, consistent molecular abnormality in PA is activation of the MAPK pathway, usually as a result of activation of BRAF. However, several lines of evidence    suggest that other signaling pathways may also play a role in the biology of these tumors. One such pathway is PI3K/AKT/mTOR which contributes to cellular proliferation and growth, and may be targeted with currently available drugs. In the past year, with the support of CBTF, we have tested numerous components of the mTOR pathway using tissue microarrays of surgically obtained PA tissue (n=114). Our data suggests that mTOR is active in a significant subset of these tumors, based on moderate to strong pS6 immunostaining in up to approximately 60% of tumors tested.

 

We currently know that mTOR in the cell exists in association with other proteins in two   different complexes: mTORC1 and mTORC2. One of our preliminary observations is that   Raptor (a component of mTORC1) is increased to a greater extent than Rictor (a component of mTORC2) in sporadic PA, while the converse was noticed in diffuse and high grade gliomas. In follow-up studies, we are analyzing the prevalence of these alterations by clinicopathologic subgroups, including tumors arising in different parts of the brain.  Additionally we are studying the mechanisms responsible for mTOR activation in pediatric low grade gliomas, and the effect of pharmacologic inhibition of the pathway on tumor growth in model systems. 

 

We are grateful to the CBTF and Tennis for Tumors for their kind support for these studies.                                             CBTF thanks Dr. Rodriguez for his very informative progress report.

 

 

Clinical and biological relevance of PI3K/AKT/mTOR pathway activation

 in pilocytic astrocytomas

 (new 2011-2012, one-year)

PI:  Fausto J. Rodriguez M.D., Johns Hopkins Medical Institute

 

Patients with pilocytic astrocytoma (PA) generally have favorable outcomes following surgical intervention, although a subset may cause significant morbidity or mortality, despite lack of atypical histologic features. Unlike diffuse gliomas, increased proliferation, invasive growth pattern, and/or necrosis do not always predict aggressive behavior in PA, although we have previously shown that frank anaplastic histologic change in the form of brisk mitotic activity with or without necrosis may portend a worse survival. Insight into the molecular alterations and pathways underlying aggressive behavior in pediatric low grade gliomas is needed, to decrease the morbidity and mortality associated with these tumors and conventional therapies. The importance of the PI3K/AKT/mTOR signaling axis has been highlighted in diffuse and high grade gliomas, and there is increasing interest in pharmacological targeting of this pathway in the pediatric setting, given recent successes reported with some low grade gliomas such as subependymal giant cell astrocytoma.    However, little is known about the role of AKT/mTOR signaling in PA, the most common primary glioma in children. Some studies have highlighted a role for mTOR activation in NF1-associated PA, and we have also reported preliminary data suggesting that it mediates phenotypic variations in NF1-associated low grade gliomas with unusual morphologies.  In addition, we have recently documented an association with phospho-AKT (ser473) and specific aggressive PA subtypes, but its clinical significance, in particular relationship to outcome, remains to be tested in a formal manner to justify specific therapeutic approaches. The goal of this proposal is to examine the role of PI3K/AKT/mTOR signaling in PA to determine if therapies targeting this pathway should be tested in children.

We are grateful to the CBTF and Tennis for Tumors for their kind

support of this grant.

The short and long-term effects of biological agents on oligodendrocyte lineage and progenitor cells in the developing brain

PI:  Joseph Scafidi, DO – Children’s Research Institute, Washington, DC

(update on progress)  Grant duration, Aug. 2011--Sept. 2013

 

The brain of children is subject to rapid growth and development. White matter is the part of the brain that is vital for communication and processing of information. White matter comprises nearly half of the human brain, and its growth and    development occurs specifically after birth and continues throughout childhood. During this critical period of white matter maturation, it is vulnerable to drugs or other agents that affect its proliferation and growth and can result in injury. Injuries to the white matter lead to life-long cognitive and sensori-motor delays.

 

Children diagnosed with brain tumors are treated with combination therapies, which often include chemotherapy, radiation and specific targeted biological therapeutic agents, which are aimed at arresting tumor growth. The same pathways involved in uncontrolled tumor growth are part of complex mechanisms imperative for normal white matter growth and maturation. Using a multidisciplinary approach, the Scafidi laboratory is studying how these specific targeted biological agents affect  normal white matter development at different developmental ages. Specifically, their studies are focused on the cellular, biochemical and  behavioral effects these agents have on the developing brain and whether its effects are developmentally age specific.   Understanding the effects these agents have on the developing brain will further our knowledge of normal brain   development and the long-term consequences of these drugs.  (Oral presentations were made at two international meeting regarding this research.)

 

Sincere appreciation to the Childhood Brain Tumor Foundation for its dedication to funding vital research initiatives!      

 

 

The Short and Long-term Effects of Biological Agents on Oligodendrocyte Lineage and Progenitor Cells in Developing Brain (new, first-year)

PI:  Joseph Scafidi, DO, Children’s Research Institute

 

Childhood is a critical time because of rapid growth and development of the brain. During this period, the brain’s white matter, composed of myelin, is the last structure to fully mature. There is growing evidence that a disturbance in white matter development contributes to significant developmental delays. There is a large gap in knowledge in how newer molecularly   targeted therapies used to treat pediatric brain tumors affect brain development, specifically white matter, during this critical period. This study, using a multidisciplinary approach, will assess and characterize the effect newly developed molecularly   targeted agents have on myelin producing cells and determine whether this is dependent on developmental stage of the brain. This study will provide a better understanding of white matter development and establish new methods to assess the effects these therapies have on the developing brain.

Please click on the links below to read grant summaries and abstracts:

2009

  • A Multi-Institutional Phase II Clinical Trial of a Novel Salvage Induction Chemotherapy Regimen-Gemcitibine Paclitaxel and Oxaliplatin (GemPOx) Followed by a Single High does Chemotherapy (HDC) and Autologous Hematopoietic Progenitor Cell Rescue (AuHPCR) for Patients with Recurrent or Progressive Intracranial Germ Cell Tumors, by Jonathan Finlay, M.D. Children's Hospital Los Angeles, CA, and Co-Principal Investigator Neha Patel, M.D., University of Wisconsin-Madison Children's Hospital
  •  

  • Hedgehog pathway activation in juvenile pilocytic astrocytoma, by Dr. Michael Cooper, Vanderbilt University, TN


  • 2008/2007

  • ABT-888, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, enhances chemotherapy and radiation against pediatric brain tumors, by Dr. Jack Su, Pediatric Hematology-Oncology, Texas Children's Cancer Center, Baylor College of Medicine
  •  

  • A role of a transcription factor, FoXM1, in cancer stem cells in pediatric brain tumors, by Ichiro Nakano, MD, UCLA, Los Angeles
  •  

  • Post transcriptional regulation of gene expression in astrocytomas, by Frederico Bolognani, MD, PhD, University of New Mexico
  •  

  • Targeting novel angiogenic factors related to AKT kinase activity in ependymoma, by Dr. Gary W. Tye and Dr. Timothy E. Van Meter, Virginia Commonwealth University


  • 2007/2006

  • Determination of TP73 Expression and Function in Medulloblastoma, by John Y.H. Kim, MD, Baylor College of Medicine, Houston, TX
  • "Role of efbB2 in the sensitivity of EGFR signaling to guinzoline based EGFR inhibitors in glioma" (2007) and "Characterizing cell resistance to small molecular inhibitors of EGFR in malignant gliomas" (2006), by Hui-Kuo Shu, MD, Emory University, Atlanta, GA
  •  

  • "MicroRNAs targeting in medulloblastoma" (2007) and "MicroRNAs targeting in medulloblastoma" (2006), by Anna Krichevsky, MD, Brigham and Womens, Boston, MA


  • 2002

  • Identification of an alternatively spliced RNA for the Ras suppressor RSU-1 in human gliomas, by Suryaprabha Chunduru, Hiroyuki Kawami, Richard Gullick, William J. Monacci, Gerard Dougherty, and Mary Lou Cutler
  •  

    Please click on the following links to read researcher comments:

  • Why Research is Important to Me, by John Y.H. Kim, MD, Baylor College of Medicine, Houston, TX
  •  

  • Why I do Brain Tumor Research, by Dr. Jack Su, Pediatric Hematology-Oncology, Texas Children's Cancer Center, Baylor College of Medicine
  •  

  • Researching Childhood Brain Tumors, by Gary Tye, MD, Virginia Commonwealth University
  • Thanks to Our Sponsors